<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216148</url>
  </required_header>
  <id_info>
    <org_study_id>FET PET 2010</org_study_id>
    <secondary_id>2008-005786-60</secondary_id>
    <nct_id>NCT03216148</nct_id>
  </id_info>
  <brief_title>18F-FET PET in Childhood Brain Tumours</brief_title>
  <official_title>A Prospective, Multicentre Trial on the Value of 18F-FET PET in the Post-therapeutic Evaluation of Childhood Brain Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      FET PET 2010 is a prospective, multicentre trial aiming to evaluate the additional benefit of
      FET PET in the assessment of remission after first line therapy and during follow-up
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      2.1 Primary objective The main objective is to evaluate the relative benefit of FET PET in
      comparison to the MRI in differentiating biologically active tumour tissue from
      therapy-related changes in paediatric brain tumours after first line therapy (Δ
      specificityFET PET to specificityMRT) 2.2 Secondary Objectives To assess sensitivity of FET
      PET in comparison with the sensitivity of MRI (Δ sensitivityFET PET to sensitivityMRT) To
      assess the positive and negative predictive values (PPV, NPV) of FET PET in comparison with
      the PPV and NPV of MRI (Δ PPVFET PET to PPVMRT, Δ NPVFET PET to NPVMRT) To evaluate
      specificity, sensitivity, PPV, and NPV by SUVratio analyses of FET PET data To evaluate the
      potential of FET PET for non-invasive tumour grading (WHO I/II vs. III/IV) by kinetic studies
      when histology is available To assess adverse events and toxicity profile

      2.3 Endpoints (Standard of truth1) 2.3.1 Primary Endpoint The primary endpoint is an event
      free survival of the follow-up period of 24 (12) months after first line therapy (confirmed
      by clinical and neuroradiological assessment) or the confirmed diagnosis of progression or
      recurrence of brain tumour tissue (confirmed by histology or clinical and neuroradiological
      assessment).

      The follow-up period for patients with a low risk of tumour recurrence after first line
      therapy, i.e. astrocytoma WHO grade I-II, oligodendroglioma WHO grade I-II, germ cell tumour,
      choroid plexus tumour, craniopharyngioma will be 24 months.

      The follow-up period for patients with a high risk of tumour recurrence after first line
      therapy, i.e. astrocytoma WHO grade III-IV, oligodendroglioma WHO grade III-IV,
      medulloblastoma, supratentorial PNET, AT/RT and other high-grade tumour lesions will be 12
      months.

      2.3.2 Secondary Endpoints To assess the secondary objectives of the FET PET 2010 study, the
      investigators will determine event free survival of the follow-up period of 24 (12) months
      after first line therapy (confirmed by clinical and neuroradiological assessment) or the
      confirmed diagnosis of progression or recurrence of brain tumour tissue (confirmed by
      histology or clinical and neuroradiological assessment).

      Histopathological characteristics of recurrent tumours (WHO grade I-IV) Safety and Toxicity
      (evolution according to CTCEA v3.0 criteria): the NCI Common Terminology Criteria for Adverse
      Events v3.0 is a descriptive terminology, that is used for Adverse Event (AE) reporting. A
      grading scale is provided for each AE term. Attached is a selection of categories, which are
      required to assess safety and toxicity of FET PET examinations.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All pediatric patients with brain Tumor receive a FET-PET Investigation in Addition to conventional MRI at the end of the first-line therapy. In case of Progression or Relapse patients may receive a second FET-PET Investigation in Addition to Routine surveillance MRI.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differentiating biologically active Tumor tissue from therapy related changes by using MRI (Magnetic Resonance Imaging) and FET PET</measure>
    <time_frame>3 years</time_frame>
    <description>The main objective is to evaluate the relative benefit of FET PET in comparison to the MRI in differentiating residual biologically active tumour tissue from therapy related changes in paediatric brain tumours after first line therapy (Δ specificityFET PET to specificityMRT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity of FET-PET when differentiating biologically active Tumor tissue from therapy-related changes by using MRI (Magnetic Resonance Imaging) and FET PET</measure>
    <time_frame>3 years</time_frame>
    <description>To assess sensitivity of FET PET in comparison with the sensitivity of MRI (Δ sensitivityFET PET to sensitivityMRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the predictive value of FET-PET when differentiating biologically active Tumor tissue from therapy-related changes by using MRI (Magnetic Resonance Imaging) and FET PET</measure>
    <time_frame>4 years</time_frame>
    <description>(PPV, NPV) of FET PET in comparison with the PPV and NPV of MRI (Δ NPVFET PET to NPVMRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Tumor grading by FET-PET when differentiating biologically active Tumor tissue from therapy-related changes by using MRI (Magnetic Resonance Imaging) and FET PET</measure>
    <time_frame>4 years</time_frame>
    <description>SUVratio analyses of FET PET data to allow for Analysis of Tumor grading when histological results are available</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety data on FET-PET in children with brain tumors</measure>
    <time_frame>3 years</time_frame>
    <description>To assess adverse events and toxicity Profile using Common Terminology Criteria for Adverse Events, CTCAE v4.03</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Brain Neoplasm</condition>
  <arm_group>
    <arm_group_label>FET-PET</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participating patients will receive a FET PET-scan with intravenous O-(2-[18F]Fluoroethyl)-L-Tyrosine parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FET-PET</intervention_name>
    <description>All participating patients will receive a FET PET-scan parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)</description>
    <arm_group_label>FET-PET</arm_group_label>
    <other_name>O-(2-[18F]Fluoroethyl)-L-Tyrosine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent (given by the parents as legal representatives of the
             patients and given by the patients)

          -  Completion of the first line therapy according to the current HIT-protocols (Current
             and subsequent paediatric primary brain tumour treatment studies approved by GPOH)

          -  Fully evaluable MRI at the end of first line therapy as confirmed by the reference
             centre of neuroradiology (Prof. Dr. M. Warmuth-Metz, Würzburg)

          -  Histology of primary brain tumour confirmed by local and reference centre of
             Neuropathology (Prof. Dr. T. Pietsch) except for patients where tumour diagnosis is
             confirmed by the reference centre of neuroradiology, i.e. NF-1 and confirmed LGG or
             patient with diffuse intrinsic pontine glioma

          -  Laboratory requirements prior to enrolment: Serum creatinine: within normal limits;
             AST, ALT: not more than 10 x above normal limits

          -  Age at inclusion: 1 year to 17 years

          -  Children below the age of 12 years are included as 2 of 3 paediatric patients with a
             brain tumour are younger than 12 years. Furthermore, young age is a known negative
             risk factor for different histological entities. Thus, this group is the most likely
             to benefit from the results of this study

          -  In all patients with reproductive potential, a pregnancy must be excluded by a
             pregnancy test before FET PET investigation

          -  Highly effective contraception in women with reproductive potential (defined as pearl
             index &lt; 1) during study participation and follow up time

          -  No participation in other clinical trials according to AMG with the same clinical
             indication over the course of the FET PET 2010 study

        Exclusion Criteria:

          -  Presence of solid non-CNS tumours or leukaemia

          -  MRI at completion of first line therapy that does not meet standard quality criteria
             for evaluation as defined by the reference centre for neuroradiology of the
             HITNetzwerk (Würzburg, Prof. Warmuth-Metz);

          -  Known allergic reactions or drug intolerance to contrast agents

          -  Patients according to § 88 StrhlSchV

          -  Pregnancy or breast-feeding

          -  Women (adolescents) of childbearing potential without highly effective contraception
             (PEARL-Index &lt; 1%), for example ParaGard IntraUterineDevice (IUD), Mirena IUD,
             Implants, Depo Provera Injections;

          -  Persons who are detained officially or legally to an official institute
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Hernáiz Driever, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michail Plotkin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vivantes Klinikum</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Uwe Behrens, PhD</last_name>
    <email>uwe.behrens@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ramona Stöckl</last_name>
    <email>ramona.stoeckl@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum Augsburg, Onkologie</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Frühwald, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, CVK, Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Hernaiz Driever, MD</last_name>
      <phone>+49 30 450 666173</phone>
      <email>pablo.hernaiz@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Bielefeld gGmbH, Onkologie</name>
      <address>
        <city>Bielefeld</city>
        <zip>33617</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norbert Jorch, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn, Onkologie</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dagmar Dilloo, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Stefan Schönberger, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte gGmbH, Onkologie</name>
      <address>
        <city>Bremen</city>
        <zip>25117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnulf Pekrun, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Onkologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Balzer, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Julia Hauer, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Onkologie</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gudrun Fleischhack, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Michael Schündeln, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Thorsten Pöppel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Forsting, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Nuklearmedizin</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp T Meyer, Prof. Dr.</last_name>
      <phone>+49 761 270 39160</phone>
      <email>sek.nuklearmedizin@uniklinik-freiburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Timo Spehl, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinik für Pädiatrische Hämatologie und Onkologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Niemeyer, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Jochen Rösler, Prof. Dr.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Zentrum für Kinder- und Jugendmedizin, Angelika-Lautenschläger-Klinik, Onkologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olaf Witt, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Till Milde, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Uwe Haberkorn, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabine Haufe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut für Neurowissenschaften und Medizin, Physik der medizinischen Bildgebung, Forschungszentrum Jülich, Nuklearmedizin</name>
      <address>
        <city>Jülich</city>
        <zip>52425</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl-Josef Langen, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln, Pädiatrische Onkologie</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thorsten Simon, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Barbara Hero, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln gGmbH</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aram Prokop, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Stephan Lobitz, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Manol Velev, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mainz, Onkologie</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Faber, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Alexandra Russo, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Matthias Miederer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kinderklinik München Schwabing, Onkologie</name>
      <address>
        <city>München</city>
        <zip>80804</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia Köhle, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Irene Teichert von Lüttichau, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nuklearmedizinische Klinik und Poliklinik</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefan Förster, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ronald Sträter, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Cornelius Kerl</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinik für Nuklearmedizin</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Weckesser, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Kambiz Rahar</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart - Olgahospital, Onkologie</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Bielack, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Stephanie Knirsch, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Nuklearmedizin</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Pöpperl, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Marcus Nicolai, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen, Onkologie</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Ebinger, Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Carl-Philipp Schwarze, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitäts-Kinderklinik Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97060</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul-Gerhardt Schlegel, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Matthias Eyrich, Prof. Dr.</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>PD Dr. Pablo Hernaiz Driever</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>FET PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

